Article
Oncology
Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Adam Walter-Croneck, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B. Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study compared the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in patients with newly diagnosed multiple myeloma. The results showed that the combination therapy group had longer progression-free survival compared to the lenalidomide monotherapy group. Further research is needed to confirm these findings.
Article
Plant Sciences
Vera Francisco, Clara Ruiz-Fernandez, Maria Gonzalez-Rodriguez, Alfonso Cordero-Barreal, Jesus Pino, Juan E. Vinuela, Francisca Lago, Javier Conde, Rodolfo Gomez, Glaucimeire Rocha Carvalho, Thiago Melo Costa Pereira, Manuel Campos-Toimil, Oreste Gualillo
Summary: The study supports the potential therapeutic effects of Virola oleifera in bone and joint diseases, but does not show evidence for improving inflammation or catabolic processes associated with arthritis. Additionally, Virola oleifera may be used as an adjuvant therapy to enhance the effects of current chemotherapeutic drugs.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Nicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, Suman Mitra, Timothy B. Campbell, Thierry Facon, Salomon Manier
Summary: The recent emergence of anti-B-cell maturation antigen (BCMA) therapies, including CAR T cells, bispecific antibodies, and antibody-drug conjugates, holds great promise in changing the strategy for treating multiple myeloma. Understanding the different mechanisms of resistance to these therapies, such as antigen escape and T-cell exhaustion, will be crucial in guiding sequential treatments with anti-BCMA therapies.
Article
Oncology
Maria Victoria Mateos, Felipe Prosper, Jesus Martin Sanchez, Enrique M. Ocio, Albert Oriol, Cristina Motllo, Jean-Marie Michot, Isidro Jarque, Rebeca Iglesias, Maria Sole, Sara Martinez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag
Summary: The triple combination of plitidepsin, BTZ, and DXM showed moderate activity and acceptable safety in adult patients with relapsed/refractory multiple myeloma.
Article
Engineering, Biomedical
Di Wu, Zongyi Wang, Jun Li, Yan Song, Manuel Everardo Mondragon Perez, Zixuan Wang, Xia Cao, Changliang Cao, Sushila Maharjan, Kenneth C. Anderson, Dharminder Chauhan, Yu Shrike Zhang
Summary: This study describes the fabrication of a high-content in vitro multiple myeloma (MM) model using a coaxial extrusion bioprinting method, which can simulate the human bone marrow microenvironment and shows that MM cells cultured in 3D models are more sensitive to drugs.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Veterinary Sciences
Hiroyuki Tani, Ryo Miyamoto, Teruki Miyazaki, Shingo Oniki, Kyoichi Tamura, Makoto Bonkobara
Summary: This case report highlights a favorable response to bortezomib treatment in a feline MM patient. The patient underwent 6 cycles of treatment with dosage adjustments for tolerability. Following treatment, clinical symptoms improved, serum globulin decreased, and pancytopenia recovered. Bortezomib appears to be a promising drug for feline MM and warrants further investigation.
BMC VETERINARY RESEARCH
(2022)
Article
Oncology
Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slordahl, Torstein Baade Ro, Eline Menu, Anne-Marit Sponaas, Magne Borset
Summary: The study demonstrates the therapeutic potential of targeting PHGDH in multiple myeloma, suggesting it as a way to overcome resistance to proteasome inhibitors.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Paul G. Richardson, Shaji K. Kumar, Tamas Masszi, Norbert Grzasko, Nizar J. Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W. Baker, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Laurent Garderet, Cyrille Touzeau, Francis K. Buadi, Jacob P. Laubach, Michele Cavo, Mohamed Darif, Richard Labotka, Deborah Berg, Philippe Moreau
Summary: The TOURMALINE-MM1 study showed that ixazomib-Rd had a significant improvement in progression-free survival compared to placebo-Rd in relapsed or refractory multiple myeloma patients, but the difference in median overall survival between the two groups was not statistically significant. Subgroup analysis indicated a greater benefit in overall survival for patients with adverse prognostic factors, and a higher percentage of patients in the ixazomib-Rd group received proteasome inhibitors as next-line therapy compared to the placebo-Rd group.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Giorgio Santoni, Consuelo Amantini, Federica Maggi, Oliviero Marinelli, Matteo Santoni, Maria Beatrice Morelli
Summary: This study evaluates the biological effects of Ibrutinib in multiple myeloma (MM) cells and finds that the expression of TRPML2 channels is related to the sensitivity to Ibrutinib, suggesting potential stratification of MM patients based on TRPML2 expression.
Article
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Summary: In patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, daratumumab plus lenalidomide and dexamethasone significantly improved overall survival and progression-free survival with no new safety concerns.
Article
Oncology
Sophia Adamia, Shruti Bhatt, Kenneth Wen, Zuzana Chyra, Geoffrey G. Fell, Yu-Tzu Tai, Marisa S. Pioso, Ivane Abiatari, Anthony Letai, David M. Dorfman, Teru Hideshima, Kenneth C. Anderson
Summary: Combination therapy targeting RAS/MAPK pathway molecules and cyclin-Ds enhances cytotoxicity and induces cell cycle arrest and mitochondrial apoptotic signaling in multiple myeloma cells.
Article
Biochemistry & Molecular Biology
Anna Staskiewicz, Erica Wong, Michael Tucker, Riya Farhin, Jonathan Park, Rana Saade, Tina Alkhazali, Tu Dang, Xinyu Wang
Summary: Multiple myeloma (MM) is a cancer characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ) is a common treatment for MM, but can be toxic at high doses. Resveratrol (RES), a compound found in grapes, inhibits MM cell growth. This study identified a synergistic combination of BTZ and a RES derivative that decreased MM cell viability by inducing apoptosis and oxidative stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biophysics
Vanille Laurent, Clementine Fronteau, Chloe Antier, Pascale Dupuis, Benoit Tessoulin, Thomas Gastinne, Beatrice Mahe, Nicolas Blin, Viviane Dubruille, Anne Lok, Patrice Chevallier, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Sophie Vantyghem, Mourad Tiab, Pascal Godmer, Sophie Sadot, Marion Loirat, Adrien Trebouet, Nicolas Cormier, Steven Le Gouill, Philippe Moreau, Cyrille Touzeau
Summary: The triplet-drug regimens VTD and VRD are standard of care induction prior to ASCT in myeloma. VRD induction was associated with more frequent use of plerixafor, increased number of apheresis, and higher collection failure rate compared to VTD. The median number of CD34-positive cells was lower in the VRD group, although the majority of patients in both groups underwent ASCT. Optimizing stem-cell collection strategy is crucial, especially in the context of tandem transplantation and incorporating anti-CD38 monoclonal antibody into induction.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biochemistry & Molecular Biology
Sang Wu Lee, Soo-Keun Yeon, Go Woon Kim, Dong Hoon Lee, Yu Hyun Jeon, Jung Yoo, So Yeon Kim, So Hee Kwon
Summary: The HDAC6-selective inhibitor A452 has been shown to overcome bortezomib resistance in multiple myeloma by decreasing the activation of resistant markers and synergistically inhibiting cancer cell growth when used in combination with other drugs. This discovery highlights the potential of A452 as a promising therapy for bortezomib-chemoresistant multiple myeloma patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)